

Docket No.
1129-208 US

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International
Application Number _____
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

_____	_____
(Application Serial No.)	(Filing Date)
_____	_____
(Application Serial No.)	(Filing Date)
_____	_____
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*


Bruce M. Collins	Registration No. 20,066
Ronald Gould	Registration No. 28,299
Diane Dunn McKay	Registration No. 34,586
Glen E. Books	Registration No. 24,950
Timothy X Gibson	Registration No. 40,618
David P. Krovoshik	Registration No. 39,258
Mary S. Kakefuda	Registration No. 39,245

Send Correspondence to: **Bruce M. Collins**
Mathews, Collins, Shepherd & Gould, P.A.
100 Thanet Circle, Suite 306
Princeton, New Jersey 08540-3662

Direct Telephone Calls to: *(name and telephone number)*
Bruce M. Collins, (609)924-8555 Telephone; (609)924-3036 Facsimile

Full name of sole or first inventor George Muller, Ph. D.	
Sole or first inventor's signature <i>George W. Muller</i>	Date 11/13/2000
Residence Bridgewater, New Jersey	
Citizenship USA	
Post Office Address 250 Windmill Court	
Bedminster, NJ 08807	

Full name of second inventor, if any Hon-Wah Man, Ph.D.	
Second inventor's signature <i>Hon-Wah Man</i>	Date 11/13/2000
Residence Neshanic Station, New Jersey	
Citizenship USA	
Post Office Address 102 Bermuda Drive	
Neshanic Station, NJ 08853	

Full name of third inventor, if any David I. Stirling, Ph.D.	
Third inventor's signature 	Date 11/13/2000
Residence Somerville, New Jersey	
Citizenship USA	
Post Office Address 3281 Round Hill Road	
Somerville, New Jersey 08876	

Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

REVOCATION AND POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Muller et al.	Confirmation No.:	9609
Serial No.:	10/262,210	Art Unit:	1625
Filed:	September 30, 2002	Examiner:	Raymond K. Covington
For:	PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES	Attorney Docket No.:	9516-192-999 (Formerly: 1129-208.1 US)

**REVOCATION AND POWER OF ATTORNEY BY
ASSIGNEE AND EXCLUSION OF INVENTOR(S) UNDER
37 C.F.R. §3.71 WITH STATEMENT UNDER 37 C.F.R. §3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Celgene Corporation, assignee of the entire right, title and interest in, to and under the invention described and claimed in the above-identified patent application, hereby revokes all previous powers of attorney and appoints hereby appoints David Weild, III (Reg. No. 21094), Barry D. Rein (Reg. No. 22411), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Rory J. Radding (Reg. No. 28749), Donald J. Goodell (Reg. No. 19766), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), Ann L. Gisolfi (Reg. No. 31956), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), Michael J. Lyons (Reg. No. 37386), Nikolaos C. George (Reg. No. 39201), Stephen S. Rabinowitz (Reg. No. 40286), Ognjan V. Shentov (Reg. No. 38051), Kenneth L. Stein (Reg. No. 38704), Andrew J. Gray (Reg. No. 41796), Henry C. Lebowitz (Reg. No. 36196), Leo Merken (Reg. No. 41192), Margaret B. Brivanlou (Reg. No. 40922), David R. Owens (Reg. No. 40756), Matthew E. Langer (Reg. No. 36343), Karen G. Horowitz (Reg. No. 35199), T. Christopher Tsang (Reg. No. 40258), and Carl P. Bretscher (Reg. No. 41635), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006, 3300 Hillview Avenue, Palo Alto, CA 94304 and 12750 High Bluff Drive, San Diego, CA 92130, all of Pennie & Edmonds LLP as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71, provided that, if any one of these attorneys ceases being affiliated with the law firm of Pennie & Edmonds LLP as partner, counsel, or employee, then the appointment of that attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all future correspondence to Pennie & Edmonds LLP, located at 1155 Avenue of the Americas, New York, New York 10036-2711, and direct all telephone calls to Pennie & Edmonds LLP at (212) 790-9090.

Customer Number: 20583

Statement Under 37 C.F.R. 3.73(b)

Celgene Corporation states that it is the assignee of the entire right, title, and interest in the patent application above by virtue of

An assignment from the inventors of Patent Application No. 09/712,550, filed November 14, 2000, now Patent No. 6,458,810 B1, to which this application claims priority. The assignment was recorded in the United States Patent and Trademark Office on May 5, 2003 at Reel 014015, Frame 0835. A copy of the recorded Assignment is attached hereto.


The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: Celgene Corporation

Date:

Dec 2, 2007

Signature:



Typed Name:

Sol J. Barer

Position/Title:

President and Chief Operating Officer

Address:

Celgene Corporation
7 Powder Horn Drive
Warren, New Jersey 07059

Enclosure